132 related articles for article (PubMed ID: 24951017)
1. Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions.
De Langhe S; De Meerleer G; De Ruyck K; Ost P; Fonteyne V; De Neve W; Thierens H
Radiother Oncol; 2014 Jul; 112(1):95-9. PubMed ID: 24951017
[TBL] [Abstract][Full Text] [Related]
2. Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene.
De Langhe S; De Ruyck K; Ost P; Fonteyne V; Werbrouck J; De Meerleer G; De Neve W; Thierens H
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):393-9. PubMed ID: 22658438
[TBL] [Abstract][Full Text] [Related]
3. Voxel-Based Analysis for Identification of Urethrovesical Subregions Predicting Urinary Toxicity After Prostate Cancer Radiation Therapy.
Mylona E; Acosta O; Lizee T; Lafond C; Crehange G; Magné N; Chiavassa S; Supiot S; Ospina Arango JD; Campillo-Gimenez B; Castelli J; de Crevoisier R
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):343-354. PubMed ID: 30716523
[TBL] [Abstract][Full Text] [Related]
4. Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population.
Mylona E; Ebert M; Kennedy A; Joseph D; Denham J; Steigler A; Supiot S; Acosta O; de Crevoisier R
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1189-1195. PubMed ID: 32673785
[TBL] [Abstract][Full Text] [Related]
5. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience.
Detti B; Baki M; Becherini C; Saieva C; Scartoni D; Giacomelli I; Trombetta L; Muntoni C; Olmetto E; Francolini G; Turkaj A; Topulli J; Ciabatti C; Carta G; Poggesi L; Delli Paoli C; Terziani F; Grassi R; Livi L
Radiol Med; 2019 May; 124(5):422-431. PubMed ID: 30607866
[TBL] [Abstract][Full Text] [Related]
6. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
[TBL] [Abstract][Full Text] [Related]
7. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
Kalakota K; Liauw SL
Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
[TBL] [Abstract][Full Text] [Related]
8. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
9. Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis.
Jani AB; Hand CM; Pelizzari CA; Roeske JC; Krauz L; Vijayakumar S
BMC Cancer; 2003 May; 3():16. PubMed ID: 12744725
[TBL] [Abstract][Full Text] [Related]
10. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
11. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
13. Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy.
Byrne K; Hruby G; Kneebone A; Whalley D; Guo L; McCloud P; Eade T
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):617-625. PubMed ID: 28416260
[TBL] [Abstract][Full Text] [Related]
14. A predictive model for dysphagia following IMRT for head and neck cancer: introduction of the EMLasso technique.
De Ruyck K; Duprez F; Werbrouck J; Sabbe N; Sofie de L; Boterberg T; Madani I; Thas O; Wilfried de N; Thierens H
Radiother Oncol; 2013 Jun; 107(3):295-9. PubMed ID: 23618501
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
[TBL] [Abstract][Full Text] [Related]
17. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
18. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
19. Image-guided radiation therapy based on helical tomotherapy in prostate cancer: minimizing toxicity.
Acevedo-Henao CM; Lopez Guerra JL; Matute R; Puebla F; Russo M; Rivin E; Sanchez-Reyes A; Ortiz MJ; Azinovic I
Oncol Res Treat; 2014; 37(6):324-30. PubMed ID: 24903763
[TBL] [Abstract][Full Text] [Related]
20. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
